ARS Pharmaceuticals, Inc. officer Eric Karas filed a Form 144 notice of proposed sale on November 9, 2026, disclosing plans to sell 139,588 shares of common stock acquired through a stock option exercise on the same date.
Richard McCathron, an officer of Hippo Holdings Inc., filed a Form 144 notice of proposed sale of 5,000 shares of common stock, with an approximate sale date of November 9, 2026, through Merrill Lynch in San Francisco.
Playtika Holding Corp. officer Uri Rubin filed a Form 144 notice of proposed sale of 220,000 common shares, submitted on November 9, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
Addus HomeCare Corporation officer and director Dirk Allison filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 98,958 shares of common stock acquired through a stock option exercise.
Bio-Rad Laboratories, Inc. officer James Barry filed a Form 144 notice of proposed sale of 1,400 shares of Bio-Rad common stock, submitted on November 9, 2026, through Morgan Stanley Smith Barney LLC Executive Financial Services.
Micron Technology, Inc. officer Sumit Sadana filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 5,000 shares of Micron common stock with an approximate sale date of November 9, 2026.
Jonathan DiVincenzo, an officer of Bio-Rad Laboratories, Inc., filed a Form 144 notice of proposed sale of securities with the SEC on November 9, 2026, disclosing plans to sell 919 shares of Bio-Rad common stock on NYSE.
TransMedics Group, Inc. director James R. Tobin filed a Form 144 notice on November 9, 2026, disclosing a proposed sale of 4,059 shares of common stock through Morgan Stanley Smith Barney LLC Executive Financial Services.
Director Nathaniel Simmons of Consensus Cloud Solutions, Inc. filed a Form 144 notice of proposed sale of 8,003 shares of common stock, with an approximate sale date of November 9, 2026, executed through Morgan Stanley Smith Barney LLC.
Director Joseph P. Slattery filed a Form 144 notice with the U.S. Securities and Exchange Commission on November 9, 2026, disclosing a proposed sale of 5,200 shares of Replimune Group, Inc. common stock through Morgan Stanley Smith Barney LLC.